PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common urinary system disease that is prone to recurrence. It typically leads to varying degrees of pelvic pain and discomfort, as well as symptoms related to the urinary system in affected patients. QianLieJinDan tablets (QLJD), a traditional Chinese medicine, have shown promising therapeutic effects on CP/CPPS in clinical practice, but the underlying mechanisms of QLJD in treating CP/CPPS have not been determined.
UNASSIGNED: To reveal the phytochemical characterization and multitarget mechanism of QLJD on CP/CPPS.
UNASSIGNED: The concentrations of the components of QLJD were determined using UHPLC-Q Exactive Orbitrap-MS. Utilizing network pharmacology approaches, the potential components, targets, and pathways involved in the treatment of CP/CPPS caused by QLJD were screened. Molecular docking calculations were employed to assess the affinity between the components of the QLJD and potential targets, revealing the optimal molecular conformation and binding site. Finally, the therapeutic efficacy and potential underlying mechanisms of QLJD were investigated through pharmacological experiments.
UNASSIGNED: In this study, a total of 35 components targeting 29 CP-related genes were identified, among which quercetin, baicalin, icariin, luteolin, and gallic acid were the major constituents. Enrichment analysis revealed that the potential targets were involved mainly in the regulation of cytokines, cell proliferation and apoptosis, and the oxidative stress response and were primarily associated with the cytokine‒cytokine receptor interaction pathway, the IL-17 signaling pathway, the Th17 cell differentiation pathway, and the JAK-STAT signaling pathway. In vivo experiments demonstrated that QLJD effectively attenuated the infiltration of CD3+ T cells and the expression of ROS in a CP/CPPS model rat prostate tissue. Furthermore, through the inhibition of IL-6 and STAT3 expression, QLJD reduced the differentiation of Th17 cells, thereby ameliorating pathological injury and prostatic index in prostate tissue.
UNASSIGNED: The potential of QLJD as an anti-CP/CPPS agent lies in its ability to interfere with the expression of IL-6 and STAT3, inhibit Th17 cell differentiation, reduce inflammatory cell infiltration in rat prostate tissue, and alleviate oxidative stress damage through its multi-component, multi-target, and multi-pathway effects.
UNASSIGNED: To reveal the phytochemical characterization and multitarget mechanism of QLJD on CP/CPPS.
UNASSIGNED: The concentrations of the components of QLJD were determined using UHPLC-Q Exactive Orbitrap-MS. Utilizing network pharmacology approaches, the potential components, targets, and pathways involved in the treatment of CP/CPPS caused by QLJD were screened. Molecular docking calculations were employed to assess the affinity between the components of the QLJD and potential targets, revealing the optimal molecular conformation and binding site. Finally, the therapeutic efficacy and potential underlying mechanisms of QLJD were investigated through pharmacological experiments.
UNASSIGNED: In this study, a total of 35 components targeting 29 CP-related genes were identified, among which quercetin, baicalin, icariin, luteolin, and gallic acid were the major constituents. Enrichment analysis revealed that the potential targets were involved mainly in the regulation of cytokines, cell proliferation and apoptosis, and the oxidative stress response and were primarily associated with the cytokine‒cytokine receptor interaction pathway, the IL-17 signaling pathway, the Th17 cell differentiation pathway, and the JAK-STAT signaling pathway. In vivo experiments demonstrated that QLJD effectively attenuated the infiltration of CD3+ T cells and the expression of ROS in a CP/CPPS model rat prostate tissue. Furthermore, through the inhibition of IL-6 and STAT3 expression, QLJD reduced the differentiation of Th17 cells, thereby ameliorating pathological injury and prostatic index in prostate tissue.
UNASSIGNED: The potential of QLJD as an anti-CP/CPPS agent lies in its ability to interfere with the expression of IL-6 and STAT3, inhibit Th17 cell differentiation, reduce inflammatory cell infiltration in rat prostate tissue, and alleviate oxidative stress damage through its multi-component, multi-target, and multi-pathway effects.
摘要：
■慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）是一种常见的泌尿系统疾病，容易复发。它通常会导致不同程度的骨盆疼痛和不适，以及与受影响患者的泌尿系统相关的症状。钱列金丹片（QLJD），中药，在临床实践中对CP/CPPS显示出有希望的治疗效果，但QLJD治疗CP/CPPS的潜在机制尚未确定。
■揭示QLJD在CP/CPPS上的植物化学表征和多靶标机制。
■使用UHPLC-QExactiveOrbitrap-MS测定QLJD组分的浓度。利用网络药理学方法，潜在的成分，目标,并筛选了QLJD引起的CP/CPPS治疗中涉及的通路。分子对接计算用于评估QLJD的组分与潜在靶标之间的亲和力，揭示了最佳的分子构象和结合位点。最后,通过药理学实验研究了QLJD的治疗效果和潜在的潜在机制.
■在这项研究中，共鉴定出针对29个CP相关基因的35个成分，其中槲皮素，黄芩苷,淫羊藿苷,木犀草素,和没食子酸是主要成分。富集分析显示潜在的靶点主要参与细胞因子的调控,细胞增殖和凋亡，和氧化应激反应，主要与细胞因子-细胞因子受体相互作用途径有关，IL-17信号通路，Th17细胞分化途径，和JAK-STAT信号通路。体内实验证明，QLJD可有效减弱CP一CPPS模型大鼠前列腺组织中CD3+T细胞的浸润和ROS的表达。此外，通过抑制IL-6和STAT3的表达，QLJD降低Th17细胞的分化，从而改善前列腺组织的病理损伤和前列腺指数。
■QLJD作为抗CP/CPPS药物的潜力在于其能够干扰IL-6和STAT3的表达，抑制Th17细胞分化，减少大鼠前列腺组织的炎症细胞浸润，并通过其多组分缓解氧化应激损伤，多目标,和多途径效应。
■揭示QLJD在CP/CPPS上的植物化学表征和多靶标机制。
■使用UHPLC-QExactiveOrbitrap-MS测定QLJD组分的浓度。利用网络药理学方法，潜在的成分，目标,并筛选了QLJD引起的CP/CPPS治疗中涉及的通路。分子对接计算用于评估QLJD的组分与潜在靶标之间的亲和力，揭示了最佳的分子构象和结合位点。最后,通过药理学实验研究了QLJD的治疗效果和潜在的潜在机制.
■在这项研究中，共鉴定出针对29个CP相关基因的35个成分，其中槲皮素，黄芩苷,淫羊藿苷,木犀草素,和没食子酸是主要成分。富集分析显示潜在的靶点主要参与细胞因子的调控,细胞增殖和凋亡，和氧化应激反应，主要与细胞因子-细胞因子受体相互作用途径有关，IL-17信号通路，Th17细胞分化途径，和JAK-STAT信号通路。体内实验证明，QLJD可有效减弱CP一CPPS模型大鼠前列腺组织中CD3+T细胞的浸润和ROS的表达。此外，通过抑制IL-6和STAT3的表达，QLJD降低Th17细胞的分化，从而改善前列腺组织的病理损伤和前列腺指数。
■QLJD作为抗CP/CPPS药物的潜力在于其能够干扰IL-6和STAT3的表达，抑制Th17细胞分化，减少大鼠前列腺组织的炎症细胞浸润，并通过其多组分缓解氧化应激损伤，多目标,和多途径效应。
